SCHEMBL776590

SCHEMBL776590

Cc1ccc(OS(=O)Oc2ccc(C)cc2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 2/20 0.48
TSHR P16473 2/20 0.46
CYP3A4 P08684 2/20 0.46
LMNA P02545 2/20 0.44
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA9 Q16790 1/20 0.43
TDP1 Q9NUW8 2/20 0.42
TEAD4 Q15561 1/20 0.41
ALDH1A1 P00352 5/20 0.39
POLB P06746 1/20 0.39
MAPT P10636 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
PKM P14618 1/20 0.39
CYP2C9 P11712 1/20 0.38
RELA Q04206 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
MMP13 P45452 1/20 0.36
HTT P42858 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3884014 0.91 HTT (0.48) ACHETSHRCYP3A4LMNACA1
SCHEMBL3883731 0.88 ACHE (0.48) ACHETSHRCYP3A4LMNACA1
SCHEMBL27769975 0.84 TDP1 (0.50) ACHETSHRLMNATDP1ALDH1A1
SCHEMBL3887583 0.83 ACHE (0.38) ACHETSHRCYP3A4LMNACA1
SCHEMBL16171303 0.83 ACHE (0.38) ACHETSHRCYP3A4LMNACA1
SCHEMBL28777056 0.82 DRD2 (0.42) ACHETSHRCYP3A4LMNATDP1
SCHEMBL16804123 0.82 ACHE (0.46) ACHETSHRCYP3A4LMNACA1
SCHEMBL497622 0.80 LMNA (0.46) ACHETSHRCYP3A4LMNACA1
SCHEMBL9846737 0.80 ACHE (0.44) ACHETSHRCYP3A4LMNACA1
SCHEMBL21077473 0.80 ACHE (0.44) ACHETSHRCYP3A4LMNACA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115369431-A Synthetic method of S- (p-tolyl) 4-methylbenzene sulfite 湖北中烟工业有限责任公司 2022-11-22 CN claimed
US-20250223282-A1 ASCORBIC ACID DERIVATIVE OR SALT THEREOF, ADDITIVE FOR POLYMERIZATION INITIATION, POLYMERIZATION INITIATOR, CURABLE COMPOSITION PREPARATION KIT, CURABLE COMPOSITION, CURED PRODUCT, AND DENTAL MATERIAL MITSUI CHEMICALS, INC. (JP) 2025-07-10 US disclosed
US-20250213436-A1 POLYMERIZATION ACCELERATOR, POLYMERIZATION INITIATOR, CURABLE COMPOSITION PREPARATION KIT, CURABLE COMPOSITION, CURED PRODUCT, AND DENTAL MATERIAL MITSUI CHEMICALS, INC. (JP) 2025-07-03 US disclosed
EP-4501974-A1 POLYMERIZATION ACCELERATOR, POLYMERIZATION INITIATOR, KIT FOR PREPARING CURABLE COMPOSITION, CURABLE COMPOSITION, CURED PRODUCT AND DENTAL MATERIAL Mitsui Chemicals, Inc. (JP) 2025-02-05 EP disclosed
EP-4484421-A1 ASCORBIC ACID DERIVATIVE OR SALT THEREOF, ADDITIVE FOR INITIATING POLYMERIZATION, POLYMERIZATION INITIATOR, KIT FOR PREPARING CURABLE COMPOSITION, CURABLE COMPOSITION, CURED PRODUCT AND DENTAL MATERIAL Mitsui Chemicals, Inc. (JP) 2025-01-01 EP disclosed
US-12100809-B2 Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery MITSUBISHI CHEMICAL CORPORATION (JP) 2024-09-24 US disclosed
WO-2024029507-A1 CURABLE COMPOSITION PREPARATION KIT, CURABLE COMPOSITION, CURED ARTICLE, AND DENTAL MATERIAL 三井化学株式会社 2024-02-08 WO disclosed
WO-2024029508-A1 KIT FOR PREPARING CURABLE COMPOSITION FOR DENTAL MATERIAL, CURABLE COMPOSITION FOR DENTAL MATERIAL, AND DENTAL MATERIAL 三井化学株式会社 2024-02-08 WO disclosed
CN-117460690-A Method for producing high-purity lithium sulfide by wet process and dry process engineering (株)定石化学 2024-01-26 CN disclosed
WO-2023182518-A1 POLYMERIZATION ACCELERATOR, POLYMERIZATION INITIATOR, KIT FOR PREPARING CURABLE COMPOSITION, CURABLE COMPOSITION, CURED PRODUCT AND DENTAL MATERIAL 三井化学株式会社 2023-09-28 WO disclosed
CN-103259044-A Nonaqueous electrolyte solution and nonaqueous electrolyte secondary battery MITSUBISHI CHEM CORP 2013-08-21 CN disclosed
US-20120177988-A1 NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY MITSUBISHI CHEMICAL CORPORATION (JP) 2012-07-12 US disclosed
CN-101432923-B Nonaqueous electrolyte solution and nonaqueous electrolyte secondary battery MITSUBISHI CHEM CORP 2012-04-18 CN disclosed
US-20120070731-A1 NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY MITSUBISHI CHEMICAL CORPORATION (JP) 2012-03-22 US disclosed
CN-102097654-A Nonaqueous electrolyte solution and nonaqueous electrolyte secondary battery MITSUBISHI CHEM CORP 2011-06-15 CN disclosed
US-20090325065-A1 NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY MITSUBISHI CHEMICAL CORPORATION (JP) 2009-12-31 US disclosed
CN-101432923-A Nonaqueous electrolyte solution and nonaqueous electrolyte secondary battery MITSUBISHI CHEM CORP (JP) 2009-05-13 CN disclosed
EP-2012386-A1 NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY Mitsubishi Chemical Corporation (JP) 2009-01-07 EP disclosed
US-4465851-A ANTIALLERGENS, ENZYME INHIBITORS NIPPON CHEMIPHAR CO., LTD. (JP) 1984-08-14 US disclosed
US-4433152-A ANTIINFLAMMATORY AGENT, ANTIALLERGEN OR ANTICOAGULANT NIPPON CHEMIPHAR CO., LTD. (JP) 1984-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250223282-A1 ASCORBIC ACID DERIVATIVE OR SALT THEREOF, ADDITIVE FOR POLYMERIZATION INITIATION, POLYMERIZATION INITIATOR, CURABLE COMPOSITION PREPARATION KIT, CURABLE COMPOSITION, CURED PRODUCT, AND DENTAL MATERIAL PROC, THEM6, RBCK1 ACHE 2308/4885TSHR 4865/4885CYP3A4 3413/4885
US-20250213436-A1 POLYMERIZATION ACCELERATOR, POLYMERIZATION INITIATOR, CURABLE COMPOSITION PREPARATION KIT, CURABLE COMPOSITION, CURED PRODUCT, AND DENTAL MATERIAL DNMT3L, CDK9, CDK6 ACHE 1523/4885TSHR 4748/4885CYP3A4 4408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.